- Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
May 7, 2026 · globenewswire.com
Basel, May 7, 2026 – Novartis, a leading global innovative medicines company, today broke ground on its new 46,000 sq. ft radioligand therapy (RLT) manufacturing site in Denton, Texas, the latest milestone in its broader $23 billion investment in US manufacturing and research. The start of construction on the company's first Texas‑based manufacturing facility brings US RLT production closer to patients across the southern US, becoming the fifth RLT site nationwide. “Radioligand therapy is transforming how we treat cancer, and expanded manufacturing is essential to delivering these therapies at scale,” said Vas Narasimhan, CEO of Novartis. “Breaking ground in Denton further strengthens our US supply chain and helps ensure patients can receive these highly personalized treatments when and where they need them.” This expansion reinforces Novartis' leadership as the first company to deliver RLT at scale, building the network capacity needed as these therapies extend into earlier stages of treatment and a broader range of cancers. Announced earlier this year, the site is expected to become operational in 2028 and create new US-based Novartis jobs in bioengineering, advanced manufacturing, quality, and operations, supporting economic growth in Denton and surrounding communities. US Under Secretary of Commerce for Industry and Security Jeffrey Kessler, Swiss Ambassador to the US Ralf Heckner, Texas State Senator Brent Hagenbuch, Texas State Representative Andy Hopper, and Denton Mayor Gerard Hudspeth joined Novartis leadership, employees, and community partners to celebrate the start of construction. “I'm pleased to welcome Novartis to Denton as their newest manufacturing location for their cancer therapies,” said Texas State Senator Brent Hagenbuch. “Their decision establishes a strong partnership and reflects the unique opportunity Denton provides to a well-educated workforce, and the unique access the new plant location will provide to the vibrant North Texas economy and rapidly growing state population.” The Texas facility bolsters the Novartis coast-to-coast RLT manufacturing network, with existing US sites in New Jersey, Indiana and California, and a new site being added in Florida. The Denton site adds to the largest US RLT manufacturing network and further builds on the company's longstanding track record of enabling >99% of doses to be administered on the planned day of treatment. Each dose of RLT is custom-made and requires precise coordination, making manufacturing reliability and proximity to treatment centers critical to delivering treatment as planned. In April 2025, Novartis committed $23 billion over five years to grow its US research and manufacturing footprint. Seven new and three expanded facilities across the country are already under construction – part of the company's broader effort to manufacture all key medicines for US patients in the US, supporting supply resilience and dependable delivery of medicines. The Denton groundbreaking builds on rapid progress across Novartis' US investment plan.
- NOVARTIS BREAKS GROUND ON DENTON, TEXAS RADIOLIGAND THERAPY SITE; CONSTRUCTION NOW UNDERWAY ACROSS ALL NEW US FACILITIES
May 7, 2026
BASEL, MAY 7, 2026 – NOVARTIS, A LEADING GLOBAL INNOVATIVE MEDICINES COMPANY, TODAY BROKE GROUND ON ITS NEW 46,000 SQ. FT RADIOLIGAND THERAPY (RLT) MANUFACTURING SITE IN DENTON, TEXAS, THE LATEST MILESTONE IN ITS BROADER $23 BILLION INVESTMENT IN US MANUFACTURING AND RESEARCH. THE START OF CONSTRUCTION ON THE COMPANY'S FIRST TEXAS‑BASED MANUFACTURING FACILITY BRINGS US RLT PRODUCTION CLOSER TO PATIENTS ACROSS THE SOUTHERN US, BECOMING THE FIFTH RLT SITE NATIONWIDE. “RADIOLIGAND THERAPY IS TRANSFORMING HOW WE TREAT CANCER, AND EXPANDED MANUFACTURING IS ESSENTIAL TO DELIVERING THESE THERAPIES AT SCALE,” SAID VAS NARASIMHAN, CEO OF NOVARTIS. “BREAKING GROUND IN DENTON FURTHER STRENGTHENS OUR US SUPPLY CHAIN AND HELPS ENSURE PATIENTS CAN RECEIVE THESE HIGHLY PERSONALIZED TREATMENTS WHEN AND WHERE THEY NEED THEM.” THIS EXPANSION REINFORCES NOVARTIS' LEADERSHIP AS THE FIRST COMPANY TO DELIVER RLT AT SCALE, BUILDING THE NETWORK CAPACITY NEEDED AS THESE THERAPIES EXTEND INTO EARLIER STAGES OF TREATMENT AND A BROADER RANGE OF CANCERS. ANNOUNCED EARLIER THIS YEAR, THE SITE IS EXPECTED TO BECOME OPERATIONAL IN 2028 AND CREATE NEW US-BASED NOVARTIS JOBS IN BIOENGINEERING, ADVANCED MANUFACTURING, QUALITY, AND OPERATIONS, SUPPORTING ECONOMIC GROWTH IN DENTON AND SURROUNDING COMMUNITIES. US UNDER SECRETARY OF COMMERCE FOR INDUSTRY AND SECURITY JEFFREY KESSLER, SWISS AMBASSADOR TO THE US RALF HECKNER, TEXAS STATE SENATOR BRENT HAGENBUCH, TEXAS STATE REPRESENTATIVE ANDY HOPPER, AND DENTON MAYOR GERARD HUDSPETH JOINED NOVARTIS LEADERSHIP, EMPLOYEES, AND COMMUNITY PARTNERS TO CELEBRATE THE START OF CONSTRUCTION. “I'M PLEASED TO WELCOME NOVARTIS TO DENTON AS THEIR NEWEST MANUFACTURING LOCATION FOR THEIR CANCER THERAPIES,” SAID TEXAS STATE SENATOR BRENT HAGENBUCH. “THEIR DECISION ESTABLISHES A STRONG PARTNERSHIP AND REFLECTS THE UNIQUE OPPORTUNITY DENTON PROVIDES TO A WELL-EDUCATED WORKFORCE, AND THE UNIQUE ACCESS THE NEW PLANT LOCATION WILL PROVIDE TO THE VIBRANT NORTH TEXAS ECONOMY AND RAPIDLY GROWING STATE POPULATION.” THE TEXAS FACILITY BOLSTERS THE NOVARTIS COAST-TO-COAST RLT MANUFACTURING NETWORK, WITH EXISTING US SITES IN NEW JERSEY, INDIANA AND CALIFORNIA, AND A NEW SITE BEING ADDED IN FLORIDA. THE DENTON SITE ADDS TO THE LARGEST US RLT MANUFACTURING NETWORK AND FURTHER BUILDS ON THE COMPANY'S LONGSTANDING TRACK RECORD OF ENABLING >99% OF DOSES TO BE ADMINISTERED ON THE PLANNED DAY OF TREATMENT. EACH DOSE OF RLT IS CUSTOM-MADE AND REQUIRES PRECISE COORDINATION, MAKING MANUFACTURING RELIABILITY AND PROXIMITY TO TREATMENT CENTERS CRITICAL TO DELIVERING TREATMENT AS PLANNED. IN APRIL 2025, NOVARTIS COMMITTED $23 BILLION OVER FIVE YEARS TO GROW ITS US RESEARCH AND MANUFACTURING FOOTPRINT. SEVEN NEW AND THREE EXPANDED FACILITIES ACROSS THE COUNTRY ARE ALREADY UNDER CONSTRUCTION – PART OF THE COMPANY'S BROADER EFFORT TO MANUFACTURE ALL KEY MEDICINES FOR US PATIENTS IN THE US, SUPPORTING SUPPLY RESILIENCE AND DEPENDABLE DELIVERY OF MEDICINES. THE DENTON GROUNDBREAKING BUILDS ON RAPID PROGRESS ACROSS NOVARTIS' US INVESTMENT PLAN.
- Novartis to cut 220 jobs as it closes German site
May 5, 2026 · reuters.com
Swiss drugmaker Novartis said on Tuesday that it is set to cut around 220 jobs in Germany as part of the planned closure of a production site by the end of 2028.
- Novartis AG (NVS) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 83/100
Apr 30, 2026 · gurufocus.com
On April 30, 2026, Novartis AG (NVS) shares rose 3.4% today, bringing the current price to $147.85. This price is within a 52-week range of $104.93 to $170.46,
- Concurrent Investment Advisors LLC Grows Position in Novartis AG $NVS
Apr 29, 2026 · defenseworld.net
Concurrent Investment Advisors LLC raised its holdings in shares of Novartis AG (NYSE: NVS) by 36.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,815 shares of the company's stock after buying an additional 3,967 shares during the quarter.
- UK's biggest drugmakers see surprise profit bump, even as pharma grapples with U.S. policies
Apr 29, 2026 · cnbc.com
Britain's largest drugmakers saw 2026 get off on a positive note, with AstraZeneca and GSK both reporting core earnings ahead of expectations on Wednesday The CEOs of a number of European pharma giants have recently said that Europe risks losing out on new medicines as drug prices in the U.S. market are tied to lower prices elsewhere under Trump's MFN policy.
- Novartis: Revenue Lags In Q1, Outlook Unchanged
Apr 28, 2026 · seekingalpha.com
Novartis missed Q1 revenue and EPS estimates, but key growth products remain strong, and full-year guidance was reaffirmed. Entresto U.S. sales eroded faster than I expected, but easier Y/Y comps and robust pipeline support a return to growth. NVS's key products Kisqali, Kesimpta, Leqvio, and Pluvicto continue to outperform, and Rhapsido is off to a strong start in the CSU market with additional clinical trial readouts on the way.
- Novartis CEO warns of reality of Trump's drug pricing policy
Apr 28, 2026 · youtube.com
Novartis' CEO warned Tuesday that the U.S. drug pricing policy under President Donald Trump poses a “very difficult situation” and the reality will soon catch up with both drugmakers and patients.
- Novartis Q1 Earnings & Revenues Miss Estimates, Stock Down
Apr 28, 2026 · zacks.com
NVS' Q1 miss reflects Entresto and Promacta generic hits, even as Kisqali, Pluvicto and Leqvio deliver strong growth and pipeline advances.
- Novartis (NVS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Apr 28, 2026 · zacks.com
Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
